Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225] Draft guidance Technology appraisal ...

Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) TA1006 12 September 2024 12 September 2024 Evinacumab for treating homozygous familial hypercholesterolaemia ...

Suggested remit: To appraise the clinical and cost effectiveness of vutrisiran within its marketing authorisation for treating transthyretin amyloidosis with cardiomyopathy ...

A list of downloadable documents created during development.

For further information on the guideline development process, please see how we develop NICE guidelines ...

Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins. NHS England ...

A list of downloadable documents created during development.

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

Latanoprost–netarsudil is recommended as an option for reducing intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension when a prostaglandin analogue alone has not ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any interests in the technology being ...

In this episode, we hear from Professor Jonathan Benger, NICE's deputy chief executive and interim director of our Centre for Guidelines. He's joined by Dr Bryony Kendall who is a GP and sits on NICE ...